Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer

  • Technology appraisal guidance
  • TA944
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators